Epigral Limited, India’s leading integrated chemical manufacturer, has announced robust Q2FY25 results, with profit after tax (PAT) rising 111% to ₹81 crore, up from ₹38 crore in Q2FY24. The company’s quarterly revenue increased by 32% year-over-year to ₹632 crore, driven by strong demand for its products.
Expansion Initiatives
it’s board has approved major expansion plans for its CPVC and Epichlorohydrin (ECH) facilities at Dahej, Gujarat. The CPVC resin capacity will be doubled to 1,50,000 tonnes per annum (TPA) by adding 75,000 TPA, while ECH capacity will be increased to 1,00,000 TPA by adding 50,000 TPA. This expansion will position Epigral’s CPVC resin facility as the largest in the world and make its ECH plant the largest in India, catering to growing domestic demand.
To further its commitment to sustainable operations, Epigral is investing in Pure.rBrine™ technology, which will recycle by-products for use in other processes, reducing waste and greenhouse gas emissions while lowering costs through an integrated production approach.
Commenting on the results, Chairman and Managing Director Mr Maulik Patel stated, “Epigral achieved a 37% topline growth in H1FY25, with a 17% rise in sales volume in high-value Derivatives and Specialty products. Our strategy to focus on value-added products, scale efficiencies, and sustainable investments will drive value creation for our shareholders.”
Vice President Mr G Shiva Kumar added that Epigral’s focus on environmental sustainability is evident in the design of its new facilities, which adhere to zero-carbon standards with open-air systems to eliminate the need for air conditioning.
Established in 2007, Epigral Limited (formerly Meghmani Finechem Ltd) is a prominent integrated chemical manufacturer in India. Its Dahej facility is recognized for its automated, integrated setup, and it houses India’s first Epichlorohydrin plant and the country’s largest CPVC plant.
Expanding into specialty chemicals, Epigral is strengthening its CPVC capacity and entering the Chlorotoluenes value chain with a dedicated R&D center. Recognized for its responsible operations, Epigral is certified by the Responsible Care program, underscoring its commitment to sustainable value for stakeholders.
